Serum β-synuclein, neurofilament light chain and glial fibrillary acidic protein as prognostic biomarkers in moderate-to-severe acute ischemic stroke.

Barba, Lorenzo; Vollmuth, Christoph; Abu-Rumeileh, Samir; Stoll, Guido; Pham, Mirko; Schuhmann, Michael K; Heuschmann, Peter U; Halbgebauer, Steffen; Kollikowski, Alexander M; Otto, Markus; Neugebauer, Hermann; Schultz, Cara; Oeckl, Patrick; Steinacker, Petra; Wolf, Judith; Haeusler, Karl Georg

doi:10.1038/s41598-023-47765-7

Items
Marc 21

001			266099
005			20240112171157.0
024	7	_	\|a pmc:PMC10684607 \|2 pmc
024	7	_	\|a 10.1038/s41598-023-47765-7 \|2 doi
024	7	_	\|a pmid:38017278 \|2 pmid
024	7	_	\|a altmetric:156899282 \|2 altmetric
037	_	_	\|a DZNE-2023-01100
041	_	_	\|a English
082	_	_	\|a 600
100	1	_	\|a Barba, Lorenzo \|b 0
245	_	_	\|a Serum β-synuclein, neurofilament light chain and glial fibrillary acidic protein as prognostic biomarkers in moderate-to-severe acute ischemic stroke.
260	_	_	\|a [London] \|c 2023 \|b Macmillan Publishers Limited, part of Springer Nature
336	7	_	\|a article \|2 DRIVER
336	7	_	\|a Output Types/Journal article \|2 DataCite
336	7	_	\|a Journal Article \|b journal \|m journal \|0 PUB:(DE-HGF)16 \|s 1701775238_15106 \|2 PUB:(DE-HGF)
336	7	_	\|a ARTICLE \|2 BibTeX
336	7	_	\|a JOURNAL_ARTICLE \|2 ORCID
336	7	_	\|a Journal Article \|0 0 \|2 EndNote
520	_	_	\|a We aimed to assess the prognostic value of serum β-synuclein (β-syn), neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in patients with moderate-to-severe acute ischemic stroke. We measured β-syn, GFAP and NfL in serum samples collected one day after admission in 30 adult patients with moderate-to-severe ischemic stroke due to middle cerebral artery (MCA) occlusion. We tested the associations between biomarker levels and clinical and radiological scores (National Institute of Health Stroke Scale scores, NIHSS, and Alberta Stroke Program Early CT Score, ASPECTS), as well as measures of functional outcome (modified Rankin Scale, mRS). Serum biomarkers were significantly associated with ASPECTS values (β-syn p = 0.0011, GFAP p = 0.0002) but not with NIHSS scores at admission. Patients who received mechanical thrombectomy and intravenous thrombolysis showed lower β-syn (p = 0.029) und NfL concentrations (p = 0.0024) compared to patients who received only mechanical thrombectomy. According to median biomarker levels, patients with high β-syn, NfL or GFAP levels showed, after therapy, lower clinical improvement (i.e., lower 24-h NIHSS change), higher NIHSS scores during hospitalization and higher mRS scores at 3-month follow-up. Elevated serum concentrations of β-syn (p = 0.016), NfL (p = 0.020) or GFAP (p = 0.010) were significantly associated with 3-month mRS of 3-6 vs. 0-2 even after accounting for age, sex and renal function. In patients with moderate-to-severe acute ischemic stroke, serum β-syn, NfL and GFAP levels associated with clinical and radiological scores at different timepoints and were able to predict short- and middle-term clinical outcomes.
536	_	_	\|a 353 - Clinical and Health Care Research (POF4-353) \|0 G:(DE-HGF)POF4-353 \|c POF4-353 \|f POF IV \|x 0
588	_	_	\|a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650	_	2	\|a Adult \|2 MeSH
650	_	2	\|a Humans \|2 MeSH
650	_	2	\|a beta-Synuclein \|2 MeSH
650	_	2	\|a Biomarkers \|2 MeSH
650	_	2	\|a Glial Fibrillary Acidic Protein \|2 MeSH
650	_	2	\|a Infarction, Middle Cerebral Artery \|2 MeSH
650	_	2	\|a Intermediate Filaments \|2 MeSH
650	_	2	\|a Ischemic Stroke \|2 MeSH
650	_	2	\|a Neurofilament Proteins \|2 MeSH
650	_	2	\|a Prognosis \|2 MeSH
650	_	2	\|a Stroke: therapy \|2 MeSH
650	_	7	\|a beta-Synuclein \|2 NLM Chemicals
650	_	7	\|a Biomarkers \|2 NLM Chemicals
650	_	7	\|a Glial Fibrillary Acidic Protein \|2 NLM Chemicals
650	_	7	\|a Neurofilament Proteins \|2 NLM Chemicals
650	_	7	\|a GFAP protein, human \|2 NLM Chemicals
650	_	7	\|a SNCB protein, human \|2 NLM Chemicals
700	1	_	\|a Vollmuth, Christoph \|b 1
700	1	_	\|a Abu-Rumeileh, Samir \|b 2
700	1	_	\|a Halbgebauer, Steffen \|0 P:(DE-2719)9002026 \|b 3 \|u dzne
700	1	_	\|a Oeckl, Patrick \|0 P:(DE-2719)9001560 \|b 4 \|u dzne
700	1	_	\|a Steinacker, Petra \|b 5
700	1	_	\|a Kollikowski, Alexander M \|b 6
700	1	_	\|a Schultz, Cara \|b 7
700	1	_	\|a Wolf, Judith \|b 8
700	1	_	\|a Pham, Mirko \|b 9
700	1	_	\|a Schuhmann, Michael K \|b 10
700	1	_	\|a Heuschmann, Peter U \|b 11
700	1	_	\|a Haeusler, Karl Georg \|b 12
700	1	_	\|a Stoll, Guido \|b 13
700	1	_	\|a Neugebauer, Hermann \|b 14
700	1	_	\|a Otto, Markus \|b 15
773	_	_	\|a 10.1038/s41598-023-47765-7 \|g Vol. 13, no. 1, p. 20941 \|0 PERI:(DE-600)2615211-3 \|n 1 \|p 20941 \|t Scientific reports \|v 13 \|y 2023 \|x 2045-2322
856	4	_	\|y OpenAccess \|u https://pub.dzne.de/record/266099/files/DZNE-2023-01100.pdf
856	4	_	\|y OpenAccess \|x pdfa \|u https://pub.dzne.de/record/266099/files/DZNE-2023-01100.pdf?subformat=pdfa
909	C	O	\|o oai:pub.dzne.de:266099 \|p openaire \|p open_access \|p VDB \|p driver \|p dnbdelivery
910	1	_	\|a External Institute \|0 I:(DE-HGF)0 \|k Extern \|b 3 \|6 P:(DE-2719)9002026
910	1	_	\|a Deutsches Zentrum für Neurodegenerative Erkrankungen \|0 I:(DE-588)1065079516 \|k DZNE \|b 4 \|6 P:(DE-2719)9001560
913	1	_	\|a DE-HGF \|b Gesundheit \|l Neurodegenerative Diseases \|1 G:(DE-HGF)POF4-350 \|0 G:(DE-HGF)POF4-353 \|3 G:(DE-HGF)POF4 \|2 G:(DE-HGF)POF4-300 \|4 G:(DE-HGF)POF \|v Clinical and Health Care Research \|x 0
914	1	_	\|y 2023
915	_	_	\|a Creative Commons Attribution CC BY 4.0 \|0 LIC:(DE-HGF)CCBY4 \|2 HGFVOC
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0200 \|2 StatID \|b SCOPUS \|d 2023-08-24
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0160 \|2 StatID \|b Essential Science Indicators \|d 2023-08-24
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)1050 \|2 StatID \|b BIOSIS Previews \|d 2023-08-24
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)1190 \|2 StatID \|b Biological Abstracts \|d 2023-08-24
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0600 \|2 StatID \|b Ebsco Academic Search \|d 2023-08-24
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)1040 \|2 StatID \|b Zoological Record \|d 2023-08-24
915	_	_	\|a JCR \|0 StatID:(DE-HGF)0100 \|2 StatID \|b SCI REP-UK : 2022 \|d 2023-08-24
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0501 \|2 StatID \|b DOAJ Seal \|d 2023-04-12T15:11:06Z
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0500 \|2 StatID \|b DOAJ \|d 2023-04-12T15:11:06Z
915	_	_	\|a WoS \|0 StatID:(DE-HGF)0113 \|2 StatID \|b Science Citation Index Expanded \|d 2023-08-24
915	_	_	\|a Fees \|0 StatID:(DE-HGF)0700 \|2 StatID \|d 2023-08-24
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0150 \|2 StatID \|b Web of Science Core Collection \|d 2023-08-24
915	_	_	\|a IF < 5 \|0 StatID:(DE-HGF)9900 \|2 StatID \|d 2023-08-24
915	_	_	\|a OpenAccess \|0 StatID:(DE-HGF)0510 \|2 StatID
915	_	_	\|a Peer Review \|0 StatID:(DE-HGF)0030 \|2 StatID \|b ASC \|d 2023-08-24
915	_	_	\|a Article Processing Charges \|0 StatID:(DE-HGF)0561 \|2 StatID \|d 2023-08-24
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)1150 \|2 StatID \|b Current Contents - Physical, Chemical and Earth Sciences \|d 2023-08-24
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0300 \|2 StatID \|b Medline \|d 2023-08-24
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0320 \|2 StatID \|b PubMed Central \|d 2023-08-24
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0199 \|2 StatID \|b Clarivate Analytics Master Journal List \|d 2023-08-24
915	_	_	\|a Peer Review \|0 StatID:(DE-HGF)0030 \|2 StatID \|b DOAJ : Anonymous peer review \|d 2023-04-12T15:11:06Z
920	1	_	\|0 I:(DE-2719)5000073 \|k AG Öckl \|l Translational Mass Spectrometry and Biomarker Research \|x 0
980	_	_	\|a journal
980	_	_	\|a VDB
980	_	_	\|a UNRESTRICTED
980	_	_	\|a I:(DE-2719)5000073
980	1	_	\|a FullTexts

Library	Collection	CLSMajor	CLSMinor	Language	Author

Marc 21

guest :: login DZNEPUB
		Search		Submit		Personalize Your alerts Your baskets Your searches		Help